Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

作者：Mohty M^*; Huebel K; Kroeger N; Aljurf M; Apperley J; Basak G W; Bazarbachi A; Douglas K; Gabriel I; Garderet L; Geraldes C; Jaksic O; Kattan M W; Koristek Z; Lanza F; Lemoli R M; Mendeleeva L; Mikala G; Mikhailova N; Nagler A; Schouten H C; Selleslag D; Suciu S; Sureda A; Worel N; Wuchter P; Chabannon C; Duarte R F

来源：Bone Marrow Transplantation, 2014, 49(7): 865-872.

DOI：10.1038/bmt.2014.39

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients%26apos; disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

• 出版日期2014-7